Evidence map›Paper›PMID 30949803›Full record

ReviewCurrent microbiology2019

Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy.

Agata Górska, Dawid Przystupski, Magdalena J Niemczura, Julita Kulbacka

2 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph

Review in Current microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 151 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 2 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05194033 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 1)

TypeinterventionalSponsorPeking UniversityRan2022 to 2022Enrolled31ConditionsSARS-CoV-2ArmsProbiotics daily, Placebo daily
NCT05195047 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 2)

TypeinterventionalSponsorPeking UniversityRan2022 to 2022Enrolled44ConditionsSARS-CoV-2Arms1 week placebo(Week 1), 1 week of probiotics(Week 1), 1 week placebo(Week 2), 1 week of probiotics(Week 2), 1 week placebo(Week 3)
3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 2 syntheses or guidelines pooled it, 332 citations in OpenAlex.

  1. Pooled it
  2. Exploring the links among inflammation and gut microbiome with psychoneurological symptoms and gastrointestinal toxicities in gynecologic cancers: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Engineered probioticScience advances · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Agata GórskaDepartment of Biological Sciences, Institute of Experimental Biology, University of Wrocław, Kanonia 6/8, 50-328, Wrocław, Poland.
Dawid PrzystupskiFaculty of Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 5, 50-345, Wrocław, Poland. dawid.przystupski@gmail.com.ORCID http://orcid.org/0000-0003-1706-3297
Magdalena J NiemczuraDepartment of Biological Sciences, Institute of Experimental Biology, University of Wrocław, Kanonia 6/8, 50-328, Wrocław, Poland.
Julita KulbackaDepartment of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556, Wrocław, Poland.
University of Wrocław · PLWroclaw Medical University · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego PO WER
6 · The paper itself

Abstract

Gut microbiota is widely considered to be one of the most important components to maintain balanced homeostasis. Looking forward, probiotic bacteria have been shown to play a significant role in immunomodulation and display antitumour properties. Bacterial strains could be responsible for detection and degradation of potential carcinogens and production of short-chain fatty acids, which affect cell death and proliferation and are known as signaling molecules in the immune system. Lactic acid bacteria present in the gut has been shown to have a role in regression of carcinogenesis due to their influence on immunomodulation, which can stand as a proof of interaction between bacterial metabolites and immune and epithelial cells. Probiotic bacteria have the ability to both increase and decrease the production of anti-inflammatory cytokines which play an important role in prevention of carcinogenesis. They are also capable of activating phagocytes in order to eliminate early-stage cancer cells. Application of heat-killed probiotic bacteria coupled with radiation had a positive influence on enhancing immunological recognition of cancer cells. In the absence of active microbiota, murine immunity to carcinogens has been decreased. There are numerous cohort studies showing the correlation between ingestion of dairy products and the risk of colon and colorectal cancer. An idea of using probiotic bacteria as vectors to administer drugs has emerged lately as several papers presenting successful results have been revealed. Within the next few years, probiotic bacteria as well as gut microbiota are likely to become an important component in cancer prevention and treatment.

Indexed as

Gastrointestinal MicrobiomeAnimalsColorectal NeoplasmsDisease Models, AnimalDysbiosisHumansImmunologic FactorsMiceProbioticsImmunologic Factors

Identifiers

PMID30949803
PMCPMC6586914
OpenAlexW2926679877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.